Healthcare IT News: The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response announced September 1 it would disburse an initial $19.8 million over the next 18 months to Deerfield, Ill.-based Takeda Vaccines to accelerate the development of a Zika vaccine for the United States.
Takeda Vaccines is a subsidiary of the Takeda Group headquartered in Japan and one the largest pharmaceutical companies in Japan and Asia. Takeda has vaccine programs for dengue, Chikungunya, norovirus, polio and pandemic influenza. Manufacturing of the Zika vaccine will occur at Takeda’s facilities in Hikari, Japan.
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now